Sensei Biotherapeutics Stock Price, News & Analysis (NASDAQ:SNSE) $0.72 +0.04 (+5.93%) (As of 12/5/2023 ET) Add Compare Share Share Today's Range$0.68▼$0.7750-Day Range$0.53▼$0.8252-Week Range$0.51▼$1.93Volume55,868 shsAverage Volume48,111 shsMarket Capitalization$17.87 millionP/E RatioN/ADividend YieldN/APrice Target$4.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainability Sensei Biotherapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside459.4% Upside$4.00 Price TargetShort InterestHealthy1.01% of Float Sold ShortDividend StrengthN/ASustainability-0.38Upright™ Environmental ScoreNews Sentiment0.00Based on 4 Articles This WeekInsider TradingAcquiring Shares$425 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($1.24) to ($1.00) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.47 out of 5 starsMedical Sector90th out of 948 stocksPharmaceutical Preparations Industry26th out of 421 stocks 3.5 Analyst's Opinion Consensus RatingSensei Biotherapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.00, Sensei Biotherapeutics has a forecasted upside of 459.4% from its current price of $0.72.Amount of Analyst CoverageSensei Biotherapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.01% of the float of Sensei Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverSensei Biotherapeutics has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Sensei Biotherapeutics has recently increased by 25.60%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldSensei Biotherapeutics does not currently pay a dividend.Dividend GrowthSensei Biotherapeutics does not have a long track record of dividend growth. Previous Next 4.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSensei Biotherapeutics has received a 77.43% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is driven by its "Basic medical research services for physical health" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Sensei Biotherapeutics is -0.38. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 4 news articles for Sensei Biotherapeutics this week, compared to 0 articles on an average week.MarketBeat Follows1 people have added Sensei Biotherapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sensei Biotherapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $425.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders25.50% of the stock of Sensei Biotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 38.52% of the stock of Sensei Biotherapeutics is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Sensei Biotherapeutics are expected to grow in the coming year, from ($1.24) to ($1.00) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sensei Biotherapeutics is -0.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sensei Biotherapeutics is -0.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSensei Biotherapeutics has a P/B Ratio of 0.21. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Sensei Biotherapeutics Stock (NASDAQ:SNSE)Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. Its Tumor Microenvironment Activated Biologics platform is designed to unleash the anti-tumor potential of T cells, as well as human monoclonal antibodies that are selectively active in the tumor microenvironment and target immune checkpoints or other critical immune pathways. The company's pipeline includes SNS-101, SNS-103, and SNS-102, monoclonal antibodies, which are in early development stages for the treatment of solid tumors. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.Read More SNSE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SNSE Stock News HeadlinesDecember 5, 2023 | americanbankingnews.comSensei Biotherapeutics (NASDAQ:SNSE) Receives New Coverage from Analysts at HC WainwrightDecember 4, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Korro Bio (KRRO), Praxis Precision Medicines (PRAX) and Sensei Biotherapeutics (SNSE)December 6, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.December 4, 2023 | msn.comHC Wainwright & Co. Initiates Coverage of Sensei Biotherapeutics (SNSE) with Buy RecommendationNovember 7, 2023 | msn.comSensei Biotherapeutics GAAP EPS of -$0.28 in-lineNovember 7, 2023 | finance.yahoo.comSensei Biotherapeutics Reports Third Quarter 2023 Financial Results and Recent Business HighlightsNovember 7, 2023 | finance.yahoo.comSensei Biotherapeutics Inc (SNSE) Reports Q3 2023 Financial ResultsNovember 3, 2023 | finance.yahoo.comSensei Biotherapeutics Reports Favorable Clinical Data for SNS-101 at 2023 SITC Annual MeetingDecember 6, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. October 25, 2023 | finance.yahoo.comSensei Biotherapeutics to Present Initial Clinical Data from Dose Escalation Trial of SNS-101 at 2023 SITC Annual MeetingOctober 24, 2023 | bizjournals.comRockville cancer therapy firm Sensei Biotherapeutics faces delisting threat from NasdaqOctober 23, 2023 | finance.yahoo.comSensei Biotherapeutics Presents Trial-in-Progress Poster for Phase 1/2 Clinical Study of SNS-101 at ESMO 2023September 27, 2023 | finance.yahoo.comSensei Biotherapeutics Announces Initiation of Combination Arm for Phase 1/2 Clinical Study of SNS-101 with Regeneron’s Libtayo®September 21, 2023 | finance.yahoo.comSensei Biotherapeutics Presents New Preclinical Data Reinforcing SNS-101 Pharmacokinetic Profile, Safety Characteristics and Mechanism of Action at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy ConferenceSeptember 13, 2023 | finance.yahoo.comSensei Biotherapeutics to Present New Preclinical Data Supporting Mechanism of Action, Pharmacokinetic Profile and Safety Characteristics for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy ConferenceAugust 30, 2023 | uk.finance.yahoo.comSNSE - Sensei Biotherapeutics, Inc.August 3, 2023 | finance.yahoo.comSensei Biotherapeutics Reports Second Quarter 2023 Financial Results and Recent Business HighlightsAugust 2, 2023 | finance.yahoo.comSensei Biotherapeutics to Participate in Canaccord Genuity’s 43rd Annual Growth ConferenceJune 13, 2023 | finance.yahoo.comSensei Biotherapeutics to Host Virtual Key Opinion Leader Event, “A New Vista for Cancer Care: Exploring SNS-101’s Potential as a Transformative Treatment Option for Patients with Solid Tumors”June 1, 2023 | finance.yahoo.comSensei Biotherapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of SNS-101, a Conditionally Active VISTA-blocking Antibody, for the Treatment of Advanced Solid TumorsMay 31, 2023 | finance.yahoo.comSensei Biotherapeutics to Participate in Jefferies Global Healthcare ConferenceMay 10, 2023 | markets.businessinsider.comCitigroup Remains a Buy on Sensei Biotherapeutics (SNSE)May 9, 2023 | finance.yahoo.comSensei Biotherapeutics Reports First Quarter 2023 Financial Results and Recent Business HighlightsApril 20, 2023 | finance.yahoo.comSensei Biotherapeutics Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for SNS-101, a Conditionally Active VISTA-Blocking AntibodyApril 18, 2023 | finance.yahoo.comSensei Biotherapeutics Presents New Preclinical Data on SNS-103 Targeting ENTPDase1 (CD39) at the American Association for Cancer Research (AACR) Annual Meeting 2023April 13, 2023 | finance.yahoo.comSensei Biotherapeutics to Participate in Canaccord Genuity’s Horizons in Oncology Virtual ConferenceMarch 30, 2023 | finance.yahoo.comSensei Biotherapeutics to Participate in Cantor Fitzgerald’s Future of Oncology Virtual SymposiumSee More Headlines Receive SNSE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sensei Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/07/2023Today12/05/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/26/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SNSE CUSIPN/A CIK1829802 Webwww.senseibio.com Phone240-243-8000FaxN/AEmployees26Year FoundedN/APrice Target and Rating Average Stock Price Target$4.00 High Stock Price Target$4.00 Low Stock Price Target$4.00 Potential Upside/Downside+459.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-48,590,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-44.68% Return on Assets-39.16% Debt Debt-to-Equity Ratio0.01 Current Ratio11.86 Quick Ratio11.86 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.37 per share Price / Book0.21Miscellaneous Outstanding Shares24,997,000Free Float18,623,000Market Cap$17.87 million OptionableNot Optionable Beta0.01 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. John K. Celebi M.B.A. (Age 51)President, CEO & Director Comp: $799.69kMs. Erin Colgan (Age 42)Chief Financial Officer Comp: $558.83kDr. Edward Van der Horst Ph.D. (Age 50)Chief Scientific Officer Comp: $444.87kMs. Lora PikeVice President of Investor Relations & CommunicationsMr. Christopher W. Gerry J.D.General Counsel & SecretaryMs. Stephanie Krebs M.B.A.M.S., Chief Business OfficerMore ExecutivesKey CompetitorsForte BiosciencesNASDAQ:FBRXIndaptus TherapeuticsNASDAQ:INDPMoleculin BiotechNASDAQ:MBRXLisata TherapeuticsNASDAQ:LSTARedHill BiopharmaNASDAQ:RDHLView All CompetitorsInsiders & InstitutionsNewtyn Management LLCSold 27,240 shares on 11/14/2023Ownership: 7.200%John CelebiBought 500 shares on 9/11/2023Total: $425.00 ($0.85/share)Apeiron Investment Group Ltd.Sold 3,441,661 sharesTotal: $5.44 M ($1.58/share)Apeiron Investment Group Ltd.Bought 2,200 shares on 2/23/2023Total: $3,542.00 ($1.61/share)View All Insider TransactionsView All Institutional Transactions SNSE Stock Analysis - Frequently Asked Questions Should I buy or sell Sensei Biotherapeutics stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sensei Biotherapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SNSE shares. View SNSE analyst ratings or view top-rated stocks. What is Sensei Biotherapeutics' stock price target for 2024? 2 Wall Street analysts have issued twelve-month target prices for Sensei Biotherapeutics' shares. Their SNSE share price targets range from $4.00 to $4.00. On average, they expect the company's share price to reach $4.00 in the next year. This suggests a possible upside of 459.4% from the stock's current price. View analysts price targets for SNSE or view top-rated stocks among Wall Street analysts. How have SNSE shares performed in 2023? Sensei Biotherapeutics' stock was trading at $1.49 on January 1st, 2023. Since then, SNSE shares have decreased by 52.0% and is now trading at $0.7150. View the best growth stocks for 2023 here. Are investors shorting Sensei Biotherapeutics? Sensei Biotherapeutics saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 168,800 shares, an increase of 25.6% from the October 31st total of 134,400 shares. Based on an average daily volume of 47,200 shares, the days-to-cover ratio is presently 3.6 days. Approximately 1.0% of the shares of the company are sold short. View Sensei Biotherapeutics' Short Interest. When is Sensei Biotherapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 26th 2024. View our SNSE earnings forecast. How were Sensei Biotherapeutics' earnings last quarter? Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) released its earnings results on Tuesday, November, 7th. The company reported ($0.28) EPS for the quarter, meeting analysts' consensus estimates of ($0.28). When did Sensei Biotherapeutics IPO? (SNSE) raised $100 million in an initial public offering (IPO) on Friday, February 5th 2021. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. Citigroup, Piper Sandler, Berenberg and Oppenheimer & Co. served as the underwriters for the IPO. Who are Sensei Biotherapeutics' major shareholders? Sensei Biotherapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Newtyn Management LLC (7.20%). Insiders that own company stock include Apeiron Investment Group Ltd, Cambrian Biopharma Inc, James Peyer, John Celebi, Robert Hamilton Pierce and Thomas G Ricks. View institutional ownership trends. How do I buy shares of Sensei Biotherapeutics? Shares of SNSE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:SNSE) was last updated on 12/6/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sensei Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.